Rosiglitazone increases bioactive testosterone and reduces waist circumference in hypogonadal men with type 2 diabetes.
The purpose of this study was to assess the effect of rosiglitazone on bioavailable, free and total testosterone levels in hypogonadal men with type 2 diabetes. Sixteen type 2 diabetic men with hypogonadism were studied before and after administration of rosiglitazone (8 mg/day) for six months, with assessments performed every two months on two consecutive days. We measured testosterone and sex hormone binding globulin (SHBG), visceral adiposity, high-sensitivity CRP (hs-CRP), lipids, microalbuminuria and blood pressure. There was a significant increase in free (p=0.01), bioavailable (p=0.007) and total testosterone (p=0.002), as well as SHBG (p=0.03) levels, with rosiglitazone treatment. Waist circumference and waist / hip ratio decreased with the improvement in insulin sensitivity and glycaemic control (p=0.01). There was also a significant reduction in hs-CRP (p=0.02) and urinary albumin excretion. No significant effect on blood pressure or the ratio of low-density lipoprotein cholesterol to high-density lipoprotein cholesterol (LDL to HDL) was seen. In conclusion, the insulin-sensitiser rosiglitazone increases bioavailable, free and total testosterone and SHBG levels in hypogonadal men with type 2 diabetes.
The Robert Hague Centre for Diabetes and Endocrinology, Barnsley NHS Foundation Trust Hospital, Gawber Road, Barnsley, S75 2EP, UK.
Dheeraj
D
Kapoor
Kevin S
KS
Channer
T Hugh
TH
Jones
D050154:Adiposity / Q000187:drug effects; D000328:Adult; D000368:Aged; D000419:Albuminuria / Q000209:etiology / Q000517:prevention & control; D001794:Blood Pressure; D049628:Body Size / Q000187:drug effects*; D002097:C-Reactive Protein / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007006:Hypogonadism / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D050152:Intra-Abdominal Fat / Q000187:drug effects; D008055:Lipids / Q000097:blood; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D000077154:Rosiglitazone; D012738:Sex Hormone-Binding Globulin / Q000378:metabolism; D013739:Testosterone / Q000097:blood*; D045162:Thiazolidinediones / Q000627:therapeutic use*; D016896:Treatment Outcome; D015854:Up-Regulation
D007004:Hypoglycemic Agents; D008055:Lipids; D012738:Sex Hormone-Binding Globulin; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D013739:Testosterone; D002097:C-Reactive Protein